HeartSciences’ MyoVista® Technology Used to Develop AI-ECG Algorithm to Identify Patients at High-Risk of Major Adverse Cardiovascular Events
Southlake, Texas, Nov. 10, 2022 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of AI, today announced that an independent study utilizing its MyoVista® proprietary technology was featured in Advocate Aurora Health’s Journal of Patient-Centered Research and Reviews, an open access, peer-reviewed medical journal devoted to advancing patient centered care practices, health outcomes, and patient experiences.
Related news for (HSCS)
- HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
- Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value
- HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone
- HeartSciences’ CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025
- HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 – Featuring CEO Andrew Simpson